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Propositions
belonging to the thesis
Pharmacogenetics of sunitinib in metastatic renal cell carcinoma
1.  CYP3A4*22 carriers show a 22.5% decrease in the clearance of sunitinib, but this effect size 
is too small to guide individual sunitinib dosing in clinical practice.  
This thesis (Chapter 3)
2.  Genetic polymorphisms in CYP3A5 or ABCB1 play an important role in predicting the need 
for dose reductions and the duration of progression-free survival in individuals treated 
with sunitinib.  
This thesis (Chapter 4)
3.  Variant allele carriers of genetic polymorphisms in CYP3A4, IL8 and IL13 have a higher risk 
of developing sunitinib-induced toxicities. 
This thesis (Chapter 5+6)
4.  PK/PD models provide a better understanding of the relationship between sunitinib 
exposure, pharmacological response and clinical outcome. 
This thesis (Chapter 8)
5.  A Genome Wide Association Study (GWAS) is more informative than a candidate gene 
study. 
This thesis (Chapter 9)
6.  The landscape for developing TKI therapy has changed, and “bench to bedside” must 
return to the bench. 
C.-H. Lee, R.J. Motzer. Urol Oncol. 2015;33(6);275–279
7.  As is the case with any other biomarker, advancing from the research space into a clinical 
application requires that criteria of validity (analytical and clinical) and utility be met.  
Gillis N, Innocenti F. Clin Pharmacol Ther. 2014;96(6):655-657
8.  While having contributed substantially to the understanding of genetic predisposition to 
drug response, current analyses of selected allelic variants do not accurately reflect the 
true interindividual variability in pharmacogenetic genes in specific patients.  
Lauschke VM, Trends Pharmacol. Sci. 2016;37(2):85-86
9. With TDM we can only adjust, while pharmacogenetics enables us to predict.
10.  Seeking for the truth in science is as challenging as flying trough the ash clouds from the 
Eyjafjallajökull.
11.  It is not the strongest of the species that survives, nor the most intelligent, but rather the 
one most adaptable to change. 
Charles Darwin (12 February 1809- 19 April 1882). In this thesis referring to resistance the 
tumor develops against sunitinib
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